Do We Still Need a Liver Biopsy? Are the Serum Fibrosis Tests Ready for Prime Time?

Clinics in Liver Disease

Volumn 10, Issue 3, 2006, Pages 513-534

  Crockett, Seth D ^a   Kaltenbach, Tonya ^b   Keeffe, Emmet B ^b  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE;

ACUTE DISEASE; AGE PLATELET INDEX; CHRONIC DISEASE; CIRRHOSIS DETERMINANT SCORE; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DISEASE MARKER; EUROPEAN LIVER FIBROSIS GROUP ALGORITHM; FIBROSIS PREDICTION INDEX; FIBROSPECT II; FIBROTEST; FORNS INDEX; HEPASCORE; HUMAN; INTERMETHOD COMPARISON; LIVER BIOPSY; LIVER DISEASE; LIVER FIBROSIS; NON INVASIVE PROCEDURE; POHL SCORE; REVIEW; SCORING SYSTEM; SCREENING TEST; SERUM FIBROSIS TEST; THROMBOCYTE COUNT;

ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BIOPSY, FINE-NEEDLE; CHOLESTEROL; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; LIVER CIRRHOSIS; PEPTIDE FRAGMENTS; PLATELET COUNT; PROCOLLAGEN; PROTHROMBIN TIME; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 33845328374     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2006.08.009     Document Type: Review

References (109)

1. Pelz L. [Diagnostic liver puncture in the work of Paul Ehrlich]. Med Monatsschr 19 8 (1965) 357-359 [in German]
2. Menghini G. One-second needle biopsy of the liver. Gastroenterology 35 2 (1958) 190-199
3. DeWitt J., LeBlanc J., McHenry L., et al. Endoscopic ultrasound-guided fine needle aspiration cytology of solid liver lesions: a large single-center experience. Am J Gastroenterol 98 9 (2003) 1976-1981
4. Strader D.B., Wright T., Thomas D.L., et al. Diagnosis, management, and treatment of hepatitis C. Hepatology 39 4 (2004) 1147-1171
5. Lok A.S., and McMahon B.J. Chronic hepatitis B. Hepatology 34 6 (2001) 1225-1241
6. European Association for the Study of the Liver. Consensus statement. EASL International Consensus Conference on Hepatitis C. Paris. February 26-28, 1999. J Hepatol 30 5 (1999) 956-961
7. de Franchis R., Hadengue A., Lau G., et al. Consensus statement (long version). EASL International Consensus Conference on Hepatitis B. September 13-14, 2002. Geneva, Switzerland. J Hepatol 39 Suppl 1 (2003) S3-S25
8. Core Working Party for Asia-Pacific Consensus on Hepatitis B and C. Consensus statements on the prevention and management of hepatitis B and hepatitis C in the Asia-Pacific region. J Gastroenterol Hepatol 15 8 (2000) 825-841
9. Liaw Y.F., Leung N., Guan R., et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int 25 3 (2005) 472-489
10. Keeffe E.B., Dieterich D.T., Han S.H., et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 4 (2006) 936-962
11. National Institutes of Health. Consensus statement on management of hepatitis C: 2002. NIH Consens State Sci Statements 19 3 (2002) 1-46
12. Garcia G., and Keeffe E.B. Liver biopsy in chronic hepatitis C: routine or selective. Am J Gastroenterol 96 11 (2001) 3053-3055
13. Reiss G., and Keeffe E.B. Role of liver biopsy in chronic liver disease: selective vs. routine. Rev Gastroenterol Disord 5 3 (2005)
14. Afdhal N.H., and Nunes D. Evaluation of liver fibrosis: a concise review. Am J Gastroenterol 99 6 (2004) 1160-1174
15. Piccinino F., Sagnelli E., Pasquale G., et al. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies. J Hepatol 2 2 (1986) 165-173
16. Thampanitchawong P., and Piratvisuth T. Liver biopsy: complications and risk factors. World J Gastroenterol 5 4 (1999) 301-304
17. Froehlich F., Lamy O., Fried M., et al. Practice and complications of liver biopsy. Results of a nationwide survey in Switzerland. Dig Dis Sci 38 8 (1993) 1480-1484
18. Wawrzynowicz-Syczewska M., Kruszewski T., and Boron-Kaczmarska A. Complications of percutaneous liver biopsy. Rom J Gastroenterol 11 2 (2002) 105-107
19. Kr'stev N. [Gallbladder puncture-a rare percutaneous liver biopsy complication]. Khirurgiia (Sofiia) 56 5-6 (2000) 32-35 [in Bulgarian]
20. Perrault J., McGill D.B., Ott B.J., et al. Liver biopsy: complications in 1000 inpatients and outpatients. Gastroenterology 74 1 (1978) 103-106
21. Afdhal NH. Expert viewpoint: staging liver fibrosis: time to abandon liver biopsy? Clinical care options for hepatitis. Available at: http://clinicaloptions.com/hep/. Accessed June, 2005.
22. Olsson R., Hagerstrand I., Broome U., et al. Sampling variability of percutaneous liver biopsy in primary sclerosing cholangitis. J Clin Pathol 48 10 (1995) 933-935
23. Pagliaro L., Rinaldi F., Craxi A., et al. Percutaneous blind biopsy versus laparoscopy with guided biopsy in diagnosis of cirrhosis. A prospective, randomized trial. Dig Dis Sci 28 1 (1983) 39-43
24. Regev A., Berho M., Jeffers L.J., et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 97 10 (2002) 2614-2618
25. Ratziu V., Charlotte F., Heurtier A., et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 128 7 (2005) 1898-1906
26. Maharaj B., Maharaj R.J., Leary W.P., et al. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet 1 8480 (1986) 523-525
27. Abdi W., Millan J.C., and Mezey E. Sampling variability on percutaneous liver biopsy. Arch Intern Med 139 6 (1979) 667-669
28. Schlichting P., Holund B., and Poulsen H. Liver biopsy in chronic aggressive hepatitis. Diagnostic reproducibility in relation to size of specimen. Scand J Gastroenterol 18 1 (1983) 27-32
29. Bravo A.A., Sheth S.G., and Chopra S. Liver biopsy. N Engl J Med 344 7 (2001) 495-500
30. Bedossa P., Dargere D., and Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 38 6 (2003) 1449-1457
31. Scheuer P.J. Liver biopsy size matters in chronic hepatitis: bigger is better. Hepatology 38 6 (2003) 1356-1358
32. Bedossa P., and Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 24 2 (1996) 289-293
33. Knodell R.G., Ishak K.G., Black W.C., et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1 5 (1981) 431-435
34. Desmet V.J., Gerber M., Hoofnagle J.H., et al. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 19 6 (1994) 1513-1520
35. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 20 1 Pt 1 (1994) 15-20
36. Bataller R., and Brenner D.A. Liver fibrosis. J Clin Invest 115 2 (2005) 209-218
37. Friedman S.L., Roll F.J., Boyles J., et al. Hepatic lipocytes: the principal collagen-producing cells of normal rat liver. Proc Natl Acad Sci U S A 82 24 (1985) 8681-8685
38. Iredale J.P., Murphy G., Hembry R.M., et al. Human hepatic lipocytes synthesize tissue inhibitor of metalloproteinases-1. Implications for regulation of matrix degradation in liver. J Clin Invest 90 1 (1992) 282-287
39. Friedman S.L. Liver fibrosis-from bench to bedside. J Hepatol 38 Suppl 1 (2003) S38-S53
40. Saitou Y., Shiraki K., Yamanaka Y., et al. Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease. World J Gastroenterol 11 4 (2005) 476-481
41. Pares A., Deulofeu R., Gimenez A., et al. Serum hyaluronate reflects hepatic fibrogenesis in alcoholic liver disease and is useful as a marker of fibrosis. Hepatology 24 6 (1996) 1399-1403
42. Walsh K.M., Timms P., Campbell S., et al. Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases -1 and -2 (TIMP-1 and TIMP-2) as noninvasive markers of liver disease in chronic hepatitis C: comparison using ROC analysis. Dig Dis Sci 44 3 (1999) 624-630
43. Lebensztejn D.M., Kaczmarski M., Sobaniec-Lotowska M., et al. Serum laminin-2 and hyaluronan predict severe liver fibrosis in children with chronic hepatitis B. Hepatology 39 3 (2004) 868-869
44. Leroy V., Monier F., Bottari S., et al. Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid. Am J Gastroenterol 99 2 (2004) 271-279
45. Guechot J., Laudat A., Loria A., et al. Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis. Clin Chem 42 4 (1996) 558-563
46. Bokarewa M., Dahlberg L., and Tarkowski A. Expression and functional properties of antibodies to tissue inhibitors of metalloproteinases (TIMPs) in rheumatoid arthritis. Arthritis Res Ther 7 5 (2005) R1014-R1022
47. Young-Min S.A., Beeton C., Laughton R., et al. Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls. Ann Rheum Dis 60 9 (2001) 846-851
48. Fassbach M., and Schwartzkopff B. Elevated serum markers for collagen synthesis in patients with hypertrophic cardiomyopathy and diastolic dysfunction. Z Kardiol 94 5 (2005) 328-335
49. Ulrich D., Noah E.M., von Heimburg D., et al. TIMP-1, MMP-2, MMP-9, and PIIINP as serum markers for skin fibrosis in patients following severe burn trauma. Plast Reconstr Surg 111 4 (2003) 1423-1431
50. Beeh K.M., Beier J., Kornmann O., et al. Sputum matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1, and their molar ratio in patients with chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and healthy subjects. Respir Med 97 6 (2003) 634-639
51. Williams A.L., and Hoofnagle J.H. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis. Gastroenterology 95 3 (1988) 734-739
52. Sheth S.G., Flamm S.L., Gordon F.D., et al. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 93 1 (1998) 44-48
53. Giannini E., Risso D., Botta F., et al. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch Intern Med 163 2 (2003) 218-224
54. Imperiale T.F., Said A.T., Cummings O.W., et al. Need for validation of clinical decision aids: use of the AST/ALT ratio in predicting cirrhosis in chronic hepatitis C. Am J Gastroenterol 95 9 (2000) 2328-2332
55. Lackner C., Struber G., Liegl B., et al. Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology 41 6 (2005) 1376-1382
56. Pohl A., Behling C., Oliver D., et al. Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. Am J Gastroenterol 96 11 (2001) 3142-3146
57. Wai C.T., Greenson J.K., Fontana R.J., et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 38 2 (2003) 518-526
58. Berg T., Sarrazin C., Hinrichsen H., et al. Does noninvasive staging of fibrosis challenge liver biopsy as a gold standard in chronic hepatitis C?. Hepatology 39 5 (2004) 1456-1457 [author reply: 1457-8]
59. Giannini E., and Testa R. Noninvasive diagnosis of fibrosis: the truth is rarely pure and never simple. Hepatology 38 5 (2003) 1312-1313 [author reply: 1313]
60. Sebastiani C., Vario A., Boccato S., et al. Predictive value of three non-invasive methods for assessing liver fibrosis in chronic hepatitis C. Hepatology 40 4 Suppl 1 (2004) 280A
61. Leroy V., Sturm N., Hilleret M., et al. What is the best non-invasive marker to estimate liver fibrosis in chronic hepatitis C (CHC) patients?. Hepatology 40 4 Suppl 1 (2004) 680A
62. Castera L., Vergniol J., Foucher J., et al. Prospective comparison of transient elastography, FibroTest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 128 2 (2005) 343-350
63. Poynard T., and Bedossa P. Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. METAVIR and CLINIVIR Cooperative Study Groups. J Viral Hepat 4 3 (1997) 199-208
64. Bonacini M., Hadi G., Govindarajan S., et al. Utility of a discriminant score for diagnosing advanced fibrosis or cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 92 8 (1997) 1302-1304
65. Forns X., Ampurdanes S., Llovet J.M., et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 36 4 Pt 1 (2002) 986-992
66. Thabut D., Simon M., Myers R.P., et al. Noninvasive prediction of fibrosis in patients with chronic hepatitis C. Hepatology 37 5 (2003) 1220-1221 [author reply: 1221]
67. Sebastiani C., Vario A., Ferrari A., et al. Combination of non invasive markers to identify liver fibrosis in HCV patients with persistently normal ALT (PNALT). Hepatology 42 4 Suppl 1 (2005) 437A
68. Sud A., Hui J.M., Farrell G.C., et al. Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index. Hepatology 39 5 (2004) 1239-1247
69. Kawser C.A., Iredale J.P., Winwood P.J., et al. Rat hepatic stellate cell expression of alpha2-macroglobulin is a feature of cellular activation: implications for matrix remodelling in hepatic fibrosis. Clin Sci (Lond) 95 2 (1998) 179-186
70. Patel K., Gordon S.C., Oh E., Smith K.M., et al. A non-invasive panel of serum fibrosis markers can reliably differentiate hepatitis C patients with minimal fibrosis from those with fibrosis stages F2-F4. Hepatology 36 4, Pt 2 (2002) 355A
71. Oh E., Smith K., Patel K., et al. An improved biomarker panel (FIBROSpect II) for differentiating mild from more severe liver fibrosis in chronic HCV patients. Gastroenterology 126 4 Suppl 2 (2004) A707
72. Patel K., Gordon S.C., Jacobson I., et al. Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J Hepatol 41 6 (2004) 935-942
73. Christensen C., Livingston S., Bruden D., et al. Comparison study of Prometheus FIBROSpect II to Knodell and Ishak fibrosis scores in Alaska Native hepatitis C patients. Gastroenterology 126 4 Suppl 2 (2004) A762
74. Rosenberg W.M., Voelker M., Thiel R., et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 127 6 (2004) 1704-1713
75. Adams L.A., Bulsara M., Rossi E., et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 51 10 (2005) 1867-1873
76. Imbert-Bismut F., Ratziu V., Pieroni L., et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 357 9262 (2001) 1069-1075
77. Poynard T., Imbert-Bismut F., Ratziu V., et al. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. J Viral Hepat 9 2 (2002) 128-133
78. Poynard T., McHutchison J., Manns M., et al. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. Hepatology 38 2 (2003) 481-492
79. Halfon P., Imbert-Bismut F., Messous D., et al. A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease. Comp Hepatol 1 1 (2002) 3
80. Poynard T., Imbert-Bismut F., Munteanu M., et al. Overview of the diagnostic value of biochemical markers of liver fibrosis, HCV FibroSURE) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol 3 1 (2004) 8
81. Borroni G., Cazzaniga M., Ceriani R., et al. Comparison of usefulness and accuracy of simple noninvasive models as predictors of cirrhosis in chronic hepatitis C. J Hepatol 40 Suppl 1 (2004) 463
82. Myers R.P., Ratziu V., Imbert-Bismut F., et al. Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis C. Am J Gastroenterol 97 9 (2002) 2419-2425
83. Myers R.P., De Torres M., Imbert-Bismut F., et al. Biochemical markers of fibrosis in patients with chronic hepatitis C: a comparison with prothrombin time, platelet count, and age-platelet index. Dig Dis Sci 48 1 (2003) 146-153
84. Myers R.P., Tainturier M.H., Ratziu V., et al. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol 39 2 (2003) 222-230
85. Myers R.P., Benhamou Y., Imbert-Bismut F., et al. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients. AIDS 17 5 (2003) 721-725
86. Naveau S., Raynard B., Ratziu V., et al. Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease. Clin Gastroenterol Hepatol 3 2 (2005) 167-174
87. Munteanu M., Ratzui V., Imbert-Bismut, et al. Precautions of use of non-invasive biochemical markers of liver injury FibroTest-ActiTest-HCV-Fibrosure (FT-AT) in 32,527 patients with chronic hepatitis C. Hepatology 40 4 Suppl 1 (2004) 686A
88. Dev A., Zekry A., Shaw L., et al. Independent Evaluation of a serum biochemical marker panel (FibroTest) to predict fibrosis in a US cohort of chronic HCV patients. Hepatology 40 4 Suppl 1 (2004) 687A
89. Ngo Y., Munteanu M., Messous D., et al. A prospective analysis of FibroTest-ActiTest-FibroSURE prognostic value in patients with chronic hepatitis C. Hepatology 42 4 Supp 1 (2005) 440A
90. Poynard T., Zoulim F., Ratzui V., et al. Kinetics of early histological response during lamivudine therapy assessed by non-invasive markers (FibroTest-ActiTest-FibroSURE) in patients with chronic hepatitis B infection. Hepatology 40 4 Suppl 1 (2004) 247A
91. Thabut D., Imbert-Bismut F., Cazals-Hatem D., et al. Diagnostic value of fibrosis biochemical markers (FibroTest-FibroSURE) for the prediction of severe portal hypertension in patients with and without cirrhosis. Hepatology (2004) 40(4 Suppl 1)z:292A
92. Thabut D., Trabut J., Massard J., et al. Biochemical markers, FibroTest-FibroSURE, a simple and non-invasive way to screen large oesophageal varices in patients with cirrhosis. Hepatology 40 4 Suppl 1 (2004) 629A
93. Patel K., Lajoie A., Heaton S., et al. Clinical use of hyaluronic acid as a predictor of fibrosis change in hepatitis C. J Gastroenterol Hepatol 18 3 (2003) 253-257
94. Le Calvez S., Thabut D., Messous D., et al. The predictive value of FibroTest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C. Hepatology 39 3 (2004) 862-863 [author reply: 863]
95. Callewaert N., Van Vlierberghe H., Van Hecke A., et al. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat Med 10 4 (2004) 429-434
96. Castera L., Van Hecke A., Trimoulet P., et al. Independent validation and comparison with Fibroscan, FibroTest and liver biopsy of clinical glycomics for the non invasive assessment of liver fibrosis in hepatitis C. Hepatology 42 4 Suppl 1 (2005) 436A
97. Mora R., Ratziu V., Bedossa P., et al. Diagnostic value of biochemical markers, FibroTest-ActiTest-HCV-FibroSURE (FT-AT) compared with serum protein profiling by SELDI-TOF Proteinchip (STP), for the diagnosis of bridging fibrosis in patients with chronic hepatitis C. Hepatology 40 4 Suppl 1 (2004) 517A
98. Gebo K.A., Herlong H.F., Torbenson M.S., et al. Role of liver biopsy in management of chronic hepatitis C: a systematic review. Hepatology 36 5 Suppl 1 (2002) S161-S172
99. Imbert-Bismut F., Messous D., Thibault V., et al. Intra-laboratory analytical variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) and reference ranges in healthy blood donors. Clin Chem Lab Med 42 3 (2004) 323-333
100. Poynard T., Munteanu M., Imbert-Bismut F., et al. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem 50 8 (2004) 1344-1355
101. Rossi E., Adams L., Prins A., et al. Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients. Clin Chem 49 3 (2003) 450-454
102. Rosenthal-Allieri M.A., Peritore M.L., et al. Analytical variability of the FibroTest proteins. Clin Biochem 38 5 (2005) 473-478
103. Park G.J., Katelaris P.H., Jones D.B., et al. The C-caffeine breath test distinguishes significant fibrosis in chronic hepatitis B and reflects response to lamivudine therapy. Aliment Pharmacol Ther 22 5 (2005) 395-403
104. Braden B., Faust D., Sarrazin U., et al. 13C-methacetin breath test as liver function test in patients with chronic hepatitis C virus infection. Aliment Pharmacol Ther 21 2 (2005) 179-185
105. Ziol M., Handra-Luca A., Kettaneh A., et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 41 1 (2005) 48-54
106. Paradis V. Glycomics: a new taste of cirrhosis marker. J Hepatol 43 5 (2005) 913-914
107. Kawada N. Analysis of proteins dominantly expressed in hepatic stellate cells of activated phenotype. Methods Mol Med 117 (2005) 371-379
108. Poon T.C., Hui A.Y., Chan H.L., et al. Prediction of liver fibrosis and cirrhosis in chronic hepatitis B infection by serum proteomic fingerprinting: a pilot study. Clin Chem 51 2 (2005) 328-335
109. Hsieh C.S., Chuang J.H., Huang C.C., et al. Evaluation of matrix metalloproteinases and their endogenous tissue inhibitors in biliary atresia-associated liver fibrosis. J Pediatr Surg 40 10 (2005) 1568-1573